Navigation Links
More freedom to take risks: DFG funds the first Reinhart Koselleck Projects
Date:12/18/2008

mentally different to reactions that are thermally or photochemically induced, as are normally studied in experimental and theoretical studies. A particular focus of this project will be on mechanochemical simulations. For instance, Marx aims to investigate numerous different systems and types of reaction. The results of these studies will initially be theoretically analysed by a combination of statistical mechanics and electronic structure. The long term goal, however, is to propose a general framework and guidelines for understanding mechanochemistry.

Prof. Dr. Erich Schrger (50), psychology, professor at the Institute of Psychology at the University of Leipzig

Humans are mentally adaptable thanks to their ability to interpret the world about them, make implicit and explicit predictions about the future, and thus evaluate the consequences of their own actions. Erich Schrger aims to expand and merge two traditionally separate fields of research in cognitive and biological psychology. He is particularly interested in automatic modelling and the systematic acquisition of auditory rules as well as the suppression of the brain's responses to autogenous auditory stimuli. By taking a primarily experimental approach, Schrger hopes to prove that the prediction and verification of what was predicted play a key role in both of these areas and that they are based on similar cognitive processes.

Dr. Roland Schle (51), molecular medicine, Head of Clinical Research at Freiburg University Hospital

Prostate cancer, one of the most common forms of cancer amongst men in the western hemisphere, is the focal point of Roland Schle's research. At present there is neither an appropriate form of clinical management, nor of long-term therapy for patients with androgen-independent prostate carcinomas. Schle therefore plans to use his Reinhart Koselleck Project funding to characterise the molecular mechanisms of this condition and derive inn
'/>"/>

Contact: Dr. Eva-Maria Streier
em.streier@dfg.de
49-228-885-2250
Deutsche Forschungsgemeinschaft
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Cost of hatchling turtles dash for freedom
2. Keck Foundation funds study of biological interactions with nanomaterials
3. Genes and environment grant funds close look at nature-nurture overlap in common diseases
4. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
5. USDA Cooperative Agreement funds mosquito project at Rutgers
6. BP funds scholarship for University of Houston to help fill industry ranks
7. OCAST funds OSU projects with commercial viability
8. BP funds energy scholarships for K20 scholars
9. National Science Foundation funds research addressing enduring questions of life
10. W.M. Keck Foundation grant funds reproductive science research
11. Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4